Founded in 2006, Avalanche Biotechnologies, Inc., is a privately held, clinical-stage biotechnology company that develops technologies and products for sustained delivery of therapeutic proteins. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet age-related macular degeneration. Avalanche's BioFactoryTM platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/22/14 | $55,000,000 | Series B |
Adage Capital Partners Deerfield Partners Redmile Group Rock Springs Capital Sabby Capital Venrock | undisclosed |
